Back to Search
Start Over
PD24-02 ASSOCIATIONS OF 5α-REDUCTASE INHIBITORS WITH DELAYED PROSTATE CANCER DIAGNOSIS AND INCREASED PROSTATE CANCER MORTALITY
- Source :
- Journal of Urology. 201
- Publication Year :
- 2019
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2019.
-
Abstract
- INTRODUCTION AND OBJECTIVES:5α-Reductase inhibitors (5-ARIs), commonly used to treat benign prostatic hyperplasia, reduce serum prostate-specific antigen (PSA) concentrations by 50%. The effect of 5-ARIs on prostate cancer detection in a PSA-screened population remains unclear. We tested the hypothesis that pre-diagnostic 5-ARI use is associated with a delayed diagnosis, more advanced disease, and higher risk of prostate cancer-specific mortality and all-cause mortality.METHODS:We linked the Veterans Affairs Informatics and Computing Infrastructure with the National Death Index to obtain patient records. The cohort included 80,875 men with American Joint Committee on Cancer stage I-IV prostate cancer diagnosed from 2001-2015. The exposure was pre-diagnostic 5-ARI use. The main outcomes were time from initial PSA elevation (defined as PSA ≥ 4 ng/mL) to diagnostic prostate biopsy, cancer grade and stage at time of diagnosis, and prostate cancer-specific and all-cause mortality. PSA was adjusted by doubling ...
- Subjects :
- Oncology
medicine.medical_specialty
education.field_of_study
Prostate biopsy
medicine.diagnostic_test
business.industry
Urology
Population
Cancer
medicine.disease
National Death Index
Prostate cancer
medicine.anatomical_structure
Prostate
Internal medicine
Cohort
medicine
business
education
Veterans Affairs
Subjects
Details
- ISSN :
- 15273792 and 00225347
- Volume :
- 201
- Database :
- OpenAIRE
- Journal :
- Journal of Urology
- Accession number :
- edsair.doi...........71bcf907abe9573686026a1c9cb17b87